AR099134A1 - Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina - Google Patents

Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina

Info

Publication number
AR099134A1
AR099134A1 ARP150100146A ARP150100146A AR099134A1 AR 099134 A1 AR099134 A1 AR 099134A1 AR P150100146 A ARP150100146 A AR P150100146A AR P150100146 A ARP150100146 A AR P150100146A AR 099134 A1 AR099134 A1 AR 099134A1
Authority
AR
Argentina
Prior art keywords
formula
compound
preparation
defined above
pharmaceutically acceptable
Prior art date
Application number
ARP150100146A
Other languages
English (en)
Spanish (es)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR099134A1 publication Critical patent/AR099134A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP150100146A 2014-01-24 2015-01-20 Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina AR099134A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNPCT/CN2014/071331 2014-01-24

Publications (1)

Publication Number Publication Date
AR099134A1 true AR099134A1 (es) 2016-06-29

Family

ID=52358790

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP150100146A AR099134A1 (es) 2014-01-24 2015-01-20 Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina
ARP200100726A AR118371A2 (es) 2014-01-24 2020-03-16 Procedimiento para la preparación de n-[(3-aminooxetan-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-quinazolin-4-amina

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP200100726A AR118371A2 (es) 2014-01-24 2020-03-16 Procedimiento para la preparación de n-[(3-aminooxetan-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-quinazolin-4-amina

Country Status (20)

Country Link
US (2) US10005770B2 (cg-RX-API-DMAC7.html)
EP (2) EP3248969B1 (cg-RX-API-DMAC7.html)
JP (1) JP6397501B2 (cg-RX-API-DMAC7.html)
KR (1) KR101841866B1 (cg-RX-API-DMAC7.html)
CN (2) CN109879837B (cg-RX-API-DMAC7.html)
AR (2) AR099134A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015208244B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016016978B1 (cg-RX-API-DMAC7.html)
CA (1) CA2934225C (cg-RX-API-DMAC7.html)
ES (2) ES2788900T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20200715T1 (cg-RX-API-DMAC7.html)
IL (1) IL245882B (cg-RX-API-DMAC7.html)
MX (1) MX368110B (cg-RX-API-DMAC7.html)
MY (1) MY176210A (cg-RX-API-DMAC7.html)
NZ (1) NZ721534A (cg-RX-API-DMAC7.html)
PL (2) PL3097098T3 (cg-RX-API-DMAC7.html)
RU (1) RU2664643C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201605916QA (cg-RX-API-DMAC7.html)
SI (2) SI3097098T1 (cg-RX-API-DMAC7.html)
WO (1) WO2015110446A1 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3298017B1 (en) 2015-05-20 2019-08-14 H. Hoffnabb-La Roche Ag Compounds for treating spinal muscular atrophy
WO2017009316A1 (en) 2015-07-16 2017-01-19 F. Hoffmann-La Roche Ag Crystalline forms of n-[(3-amino-3-oxetanyl)methyl]-2-(2,3-dihydro-1,1 -dioxido-1,4-benzothiazepin-4(5 h)-yl)-6-methyl-4-quinazolinamine for the treatment of respiratory syncytial virus (rsv) infections
MY197231A (en) 2015-07-22 2023-06-06 Enanta Pharm Inc Benzodiazepine derivatives as rsv inhibitors
AU2016353961B2 (en) 2015-11-12 2019-08-29 F. Hoffmann-La Roche Ag Compositions for treating spinal muscular atrophy
CA3119019C (en) 2015-12-10 2024-06-11 Ptc Therapeutics, Inc. Compounds and methods for treating huntington's disease
EP3386978B1 (en) 2015-12-10 2021-01-27 H. Hoffnabb-La Roche Ag Bridged piperidine derivatives
CN108017599B (zh) * 2016-11-04 2020-03-03 上海爱科百发生物医药技术有限公司 [3-(胺甲基)-氧杂环丁烷-3-基]氨基甲酸对甲氧基苄酯对氯苯甲酸盐合成方法
EP4151627A1 (en) 2017-06-05 2023-03-22 PTC Therapeutics, Inc. Compounds for treating huntington's disease
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
CN111163838B (zh) 2017-06-28 2023-03-28 Ptc医疗公司 用于治疗亨廷顿氏病的方法
WO2019006295A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
CN111386118B (zh) 2017-09-29 2023-05-09 英安塔制药有限公司 作为rsv抑制剂的组合药物剂
BR112020019373A2 (pt) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
WO2020005882A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
WO2020190935A1 (en) 2019-03-18 2020-09-24 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as rsv inhibitors
CA3139821A1 (en) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
PH12022550783A1 (en) 2019-10-04 2023-07-31 Enanta Pharm Inc Antiviral heterocyclic compounds
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
WO2021083290A1 (en) 2019-10-31 2021-05-06 Shanghai Ark Biopharmaceutical Co. Ltd. Respiratory syncytial virus fusion protein inhibitor compositions and methods for the treatment and prophylaxis of rsv diseases using the same
CN113149977A (zh) * 2020-01-22 2021-07-23 苏州爱科百发生物医药技术有限公司 一类呼吸道合胞病毒抑制剂的合成与用途
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
CN111548325A (zh) * 2020-05-16 2020-08-18 西安都创医药科技有限公司 一种卤代苯并硫氮杂卓化合物的制备方法及其制备的产品及其应用
CN111518055A (zh) * 2020-05-16 2020-08-11 西安都创医药科技有限公司 一种苯并硫氮杂卓氧化物的制备方法及其制备的产品及其应用
CN111620838A (zh) * 2020-05-16 2020-09-04 西安都创医药科技有限公司 一种氯代苯并硫氮杂卓化合物的制备方法及其制备的产品及其应用
CN111574475B (zh) * 2020-06-03 2022-09-20 西安都创医药科技有限公司 卤代苯并硫杂卓氧化物的制备方法及其制备的产品及其应用
WO2022010882A1 (en) 2020-07-07 2022-01-13 Enanta Pharmaceuticals, Inc, Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors
WO2022086840A1 (en) 2020-10-19 2022-04-28 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
US12612412B2 (en) 2021-02-26 2026-04-28 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
MX2023009961A (es) 2021-02-26 2023-09-05 Enanta Pharm Inc Compuestos heterociclicos antivirales.
AR129003A1 (es) 2022-04-07 2024-07-03 Enanta Pharm Inc Compuestos heterocíclicos antivirales
WO2023211997A1 (en) 2022-04-27 2023-11-02 Enanta Pharmaceuticals, Inc. Antiviral compounds
EP4745139A1 (en) * 2023-07-10 2026-05-20 CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. COMPOUND FOR THE TREATMENT AND PREVENTION OF INFECTIOUS DISEASES CAUSED BY THE RESPIRATORY SYNCYTIAL VIRUS
WO2026149524A1 (zh) * 2025-01-09 2026-07-16 石药集团中奇制药技术(石家庄)有限公司 氨基吡咯烷类衍生物及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1383409A (en) * 1972-09-09 1974-02-12 Pfizer Ltd Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them
SE9901573D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
CA2516329A1 (en) * 2003-02-21 2004-09-02 Pharmacia & Upjohn Company Llc Exo-(t-butyl 2r(+))-2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate, intermediates, and process to prepare and isolate them
US20050009817A1 (en) * 2003-04-30 2005-01-13 Jennifer Savoy Substituted heteroaryls
DE102004045648A1 (de) * 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
JP4899385B2 (ja) * 2005-09-06 2012-03-21 宇部興産株式会社 3−アミノメチルオキセタン化合物の製法
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
JP2013534233A (ja) * 2010-08-20 2013-09-02 セルゾーム リミティッド 選択的jak阻害剤としてのヘテロシクリルピラゾロピリミジン類似体
US8871756B2 (en) * 2011-08-11 2014-10-28 Hoffmann-La Roche Inc. Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease
JP2014530225A (ja) 2011-10-11 2014-11-17 エフ.ホフマン−ラ ロシュアーゲーF.Hoffmann−La Roche Aktiengesellschaft 呼吸器合胞体ウイルス疾患の処置および予防のための化合物
JP2016518421A (ja) * 2013-05-14 2016-06-23 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 呼吸器合胞体ウイルス感染症の処置および予防のためのアザ−オキソ−インドール

Also Published As

Publication number Publication date
CA2934225A1 (en) 2015-07-30
JP2017503843A (ja) 2017-02-02
CN106414436A (zh) 2017-02-15
MX2016009514A (es) 2016-10-26
IL245882B (en) 2019-09-26
PL3248969T3 (pl) 2020-06-29
KR20160102055A (ko) 2016-08-26
AR118371A2 (es) 2021-09-29
AU2015208244A1 (en) 2016-06-16
CN106414436B (zh) 2019-04-23
SI3097098T1 (sl) 2020-07-31
RU2016133187A3 (cg-RX-API-DMAC7.html) 2018-02-28
EP3097098B1 (en) 2020-03-04
US10005770B2 (en) 2018-06-26
HRP20200715T1 (hr) 2020-07-24
US10253022B2 (en) 2019-04-09
EP3097098A1 (en) 2016-11-30
BR112016016978B1 (pt) 2022-08-16
NZ721534A (en) 2018-02-23
JP6397501B2 (ja) 2018-09-26
MY176210A (en) 2020-07-24
KR101841866B1 (ko) 2018-03-23
RU2016133187A (ru) 2018-02-28
BR112016016978A2 (cg-RX-API-DMAC7.html) 2017-08-08
SI3248969T1 (sl) 2020-07-31
MX368110B (es) 2019-09-18
EP3248969A1 (en) 2017-11-29
US20180265505A1 (en) 2018-09-20
PL3097098T3 (pl) 2020-06-29
IL245882A0 (en) 2016-08-02
ES2788900T3 (es) 2020-10-23
EP3248969B1 (en) 2020-03-04
AU2015208244B2 (en) 2017-11-02
US20160326160A1 (en) 2016-11-10
HRP20200680T1 (hr) 2020-07-24
ES2789798T3 (es) 2020-10-26
RU2664643C2 (ru) 2018-08-21
CA2934225C (en) 2018-09-04
CN109879837A (zh) 2019-06-14
SG11201605916QA (en) 2016-08-30
WO2015110446A1 (en) 2015-07-30
CN109879837B (zh) 2023-06-09

Similar Documents

Publication Publication Date Title
AR118371A2 (es) Procedimiento para la preparación de n-[(3-aminooxetan-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-quinazolin-4-amina
AR103222A1 (es) Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina
AR106141A1 (es) Métodos e intermediarios para la preparación de derivados de ácidos biliares
EA201490647A1 (ru) Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции
MX375970B (es) Compuestos de triazolopirimidina y usos de los mismos.
ECSP13012417A (es) Derivados de ácido napht-2-ilacético para tratar sida
EA201490419A1 (ru) Соединения для лечения и профилактики респираторного синцитиального вирусного заболевания
AR093659A1 (es) Derivados ciclicos de nucleosidos y usos de los mismos
CY1118478T1 (el) Παραγωγα τυπου αζαϊνδαζολιου ή διαζαϊνδαζολιου για τη θεραπεια του πονου
HK1244708A1 (zh) 作爲fxr/tgr5激动剂的胆汁酸类似物及其使用方法
MX375170B (es) Compuestos de amida para el tratamiento de vih.
PE20151542A1 (es) Compuestos de tetrahidropirrolotiazina
CY1116791T1 (el) 4-αρυλ-ν-φαινυλ-1,3,5-τριαζιν-αμινες που περιεχουν μια ομαδα σουλφοξιμινης
TN2015000391A1 (en) Compounds and compositions for the treatment of parasitic diseases
EA201791019A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
EA201590197A1 (ru) Соединения для лечения парамиксовирусных вирусных инфекций
EA201300604A1 (ru) Соединения, предназначенные для лечения респираторно-синцитиальных вирусных инфекций
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
DOP2017000034A (es) Compuestos de imidazopiridazina
EA201792597A3 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
MX384120B (es) Composiciones de vacuna.
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
AR109328A1 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana

Legal Events

Date Code Title Description
FG Grant, registration